Genomic Health (GHDX) Rating Lowered to Neutral at LADENBURG THALM/SH SH

Genomic Health (NASDAQ:GHDX) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a report issued on Wednesday, The Fly reports.

GHDX has been the topic of several other research reports. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “strong sell” rating in a report on Friday, March 9th. ValuEngine upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 7th. Deutsche Bank lifted their price target on shares of Genomic Health from $32.00 to $34.00 and gave the company a “hold” rating in a report on Thursday, May 3rd. BidaskClub raised Genomic Health from a “hold” rating to a “buy” rating in a research report on Friday, March 30th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research report on Thursday, March 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $34.38.

Shares of Genomic Health stock opened at $50.70 on Wednesday. Genomic Health has a 52-week low of $26.54 and a 52-week high of $53.65. The company has a market capitalization of $1.77 billion, a PE ratio of 5,070.00 and a beta of 0.64.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.08. The business had revenue of $92.60 million for the quarter, compared to analysts’ expectations of $88.95 million. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.02) earnings per share. research analysts forecast that Genomic Health will post 0.47 EPS for the current fiscal year.

In other news, insider James J. Vaughn sold 1,497 shares of Genomic Health stock in a transaction dated Wednesday, May 2nd. The stock was sold at an average price of $32.50, for a total value of $48,652.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $38.09, for a total value of $380,900.00. The disclosure for this sale can be found here. Insiders have sold 125,411 shares of company stock valued at $5,405,415 in the last three months. Insiders own 45.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Genomic Health by 120.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock worth $101,000 after purchasing an additional 1,619 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Genomic Health in the 4th quarter worth about $242,000. Virtu Financial LLC purchased a new position in shares of Genomic Health in the 4th quarter worth about $261,000. Guggenheim Capital LLC purchased a new position in shares of Genomic Health in the 1st quarter worth about $264,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Genomic Health in the 4th quarter worth about $301,000. 89.90% of the stock is owned by hedge funds and other institutional investors.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

The Fly

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply